Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients

Autores
Dominguez, Raul Omar; Marschoff, Enrique Ricardo; Gonzalez, Silvia Estela; Repetto, Marisa Gabriela; Serra, Jorge Alberto
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Aim: To evaluate the cognitive performance of a homogeneous population of Alzheimer's disease (AD), non-demented Type 2 Diabetes Mellitus (DIAB), demented with concomitant diseases (AD+DIAB) and healthy control subjects. AD is a progressive dementia disorder characterized clinically by impairment of memory, cognition and behavior. Recently, a major research interest in AD has been placed on early evaluation. Diabetes is one of the clinical conditions that represent the greatest risk of developing oxidative stress and dementia. Glucose overload, leading to the development of impaired-induced insulin secretion in DIAB and has been suggested to slow or deter AD pathogenesis. Methods: The degree of cognitive impairment was determined on the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) and the Folstein's Mini Mental State Examination (MMSE); the severity of dementia was quantified applying the Clinical Dementia Rating (CDR) test; the Hamilton test was employed to evaluate depressive conditions; the final population studied was 101 subjects. Results: The cognitive deterioration is statistically significantly lower (p<0.05) in AD+DIAB patients as compared with AD patients. Conclusions: In this longitudinal study the superimposed diabetic condition was associated with a lower rate of cognitive decline, while diabetic non-demented patients and controls present normal scores. © 2012 Elsevier Ireland Ltd.
Fil: Dominguez, Raul Omar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Marschoff, Enrique Ricardo. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Gonzalez, Silvia Estela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Repetto, Marisa Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina
Fil: Serra, Jorge Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina
Materia
Alzheimer'S Disease
Cognitive Performance
Cognitive Tests
Type 2 Diabetes Mellitus
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/67436

id CONICETDig_b9e18b987b5d2c8b728be32a944f7aaf
oai_identifier_str oai:ri.conicet.gov.ar:11336/67436
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patientsDominguez, Raul OmarMarschoff, Enrique RicardoGonzalez, Silvia EstelaRepetto, Marisa GabrielaSerra, Jorge AlbertoAlzheimer'S DiseaseCognitive PerformanceCognitive TestsType 2 Diabetes Mellitushttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Aim: To evaluate the cognitive performance of a homogeneous population of Alzheimer's disease (AD), non-demented Type 2 Diabetes Mellitus (DIAB), demented with concomitant diseases (AD+DIAB) and healthy control subjects. AD is a progressive dementia disorder characterized clinically by impairment of memory, cognition and behavior. Recently, a major research interest in AD has been placed on early evaluation. Diabetes is one of the clinical conditions that represent the greatest risk of developing oxidative stress and dementia. Glucose overload, leading to the development of impaired-induced insulin secretion in DIAB and has been suggested to slow or deter AD pathogenesis. Methods: The degree of cognitive impairment was determined on the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) and the Folstein's Mini Mental State Examination (MMSE); the severity of dementia was quantified applying the Clinical Dementia Rating (CDR) test; the Hamilton test was employed to evaluate depressive conditions; the final population studied was 101 subjects. Results: The cognitive deterioration is statistically significantly lower (p<0.05) in AD+DIAB patients as compared with AD patients. Conclusions: In this longitudinal study the superimposed diabetic condition was associated with a lower rate of cognitive decline, while diabetic non-demented patients and controls present normal scores. © 2012 Elsevier Ireland Ltd.Fil: Dominguez, Raul Omar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Marschoff, Enrique Ricardo. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Gonzalez, Silvia Estela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Repetto, Marisa Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; ArgentinaFil: Serra, Jorge Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; ArgentinaElsevier Ireland2012-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/67436Dominguez, Raul Omar; Marschoff, Enrique Ricardo; Gonzalez, Silvia Estela; Repetto, Marisa Gabriela; Serra, Jorge Alberto; Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients; Elsevier Ireland; Diabetes Research and Clinical Practice; 98; 1; 10-2012; 68-740168-8227CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.diabres.2012.05.013info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S0168822712001763info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:57:07Zoai:ri.conicet.gov.ar:11336/67436instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:57:08.283CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients
title Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients
spellingShingle Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients
Dominguez, Raul Omar
Alzheimer'S Disease
Cognitive Performance
Cognitive Tests
Type 2 Diabetes Mellitus
title_short Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients
title_full Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients
title_fullStr Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients
title_full_unstemmed Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients
title_sort Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients
dc.creator.none.fl_str_mv Dominguez, Raul Omar
Marschoff, Enrique Ricardo
Gonzalez, Silvia Estela
Repetto, Marisa Gabriela
Serra, Jorge Alberto
author Dominguez, Raul Omar
author_facet Dominguez, Raul Omar
Marschoff, Enrique Ricardo
Gonzalez, Silvia Estela
Repetto, Marisa Gabriela
Serra, Jorge Alberto
author_role author
author2 Marschoff, Enrique Ricardo
Gonzalez, Silvia Estela
Repetto, Marisa Gabriela
Serra, Jorge Alberto
author2_role author
author
author
author
dc.subject.none.fl_str_mv Alzheimer'S Disease
Cognitive Performance
Cognitive Tests
Type 2 Diabetes Mellitus
topic Alzheimer'S Disease
Cognitive Performance
Cognitive Tests
Type 2 Diabetes Mellitus
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Aim: To evaluate the cognitive performance of a homogeneous population of Alzheimer's disease (AD), non-demented Type 2 Diabetes Mellitus (DIAB), demented with concomitant diseases (AD+DIAB) and healthy control subjects. AD is a progressive dementia disorder characterized clinically by impairment of memory, cognition and behavior. Recently, a major research interest in AD has been placed on early evaluation. Diabetes is one of the clinical conditions that represent the greatest risk of developing oxidative stress and dementia. Glucose overload, leading to the development of impaired-induced insulin secretion in DIAB and has been suggested to slow or deter AD pathogenesis. Methods: The degree of cognitive impairment was determined on the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) and the Folstein's Mini Mental State Examination (MMSE); the severity of dementia was quantified applying the Clinical Dementia Rating (CDR) test; the Hamilton test was employed to evaluate depressive conditions; the final population studied was 101 subjects. Results: The cognitive deterioration is statistically significantly lower (p<0.05) in AD+DIAB patients as compared with AD patients. Conclusions: In this longitudinal study the superimposed diabetic condition was associated with a lower rate of cognitive decline, while diabetic non-demented patients and controls present normal scores. © 2012 Elsevier Ireland Ltd.
Fil: Dominguez, Raul Omar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Marschoff, Enrique Ricardo. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Gonzalez, Silvia Estela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Repetto, Marisa Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina
Fil: Serra, Jorge Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina
description Aim: To evaluate the cognitive performance of a homogeneous population of Alzheimer's disease (AD), non-demented Type 2 Diabetes Mellitus (DIAB), demented with concomitant diseases (AD+DIAB) and healthy control subjects. AD is a progressive dementia disorder characterized clinically by impairment of memory, cognition and behavior. Recently, a major research interest in AD has been placed on early evaluation. Diabetes is one of the clinical conditions that represent the greatest risk of developing oxidative stress and dementia. Glucose overload, leading to the development of impaired-induced insulin secretion in DIAB and has been suggested to slow or deter AD pathogenesis. Methods: The degree of cognitive impairment was determined on the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) and the Folstein's Mini Mental State Examination (MMSE); the severity of dementia was quantified applying the Clinical Dementia Rating (CDR) test; the Hamilton test was employed to evaluate depressive conditions; the final population studied was 101 subjects. Results: The cognitive deterioration is statistically significantly lower (p<0.05) in AD+DIAB patients as compared with AD patients. Conclusions: In this longitudinal study the superimposed diabetic condition was associated with a lower rate of cognitive decline, while diabetic non-demented patients and controls present normal scores. © 2012 Elsevier Ireland Ltd.
publishDate 2012
dc.date.none.fl_str_mv 2012-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/67436
Dominguez, Raul Omar; Marschoff, Enrique Ricardo; Gonzalez, Silvia Estela; Repetto, Marisa Gabriela; Serra, Jorge Alberto; Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients; Elsevier Ireland; Diabetes Research and Clinical Practice; 98; 1; 10-2012; 68-74
0168-8227
CONICET Digital
CONICET
url http://hdl.handle.net/11336/67436
identifier_str_mv Dominguez, Raul Omar; Marschoff, Enrique Ricardo; Gonzalez, Silvia Estela; Repetto, Marisa Gabriela; Serra, Jorge Alberto; Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients; Elsevier Ireland; Diabetes Research and Clinical Practice; 98; 1; 10-2012; 68-74
0168-8227
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.diabres.2012.05.013
info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S0168822712001763
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Ireland
publisher.none.fl_str_mv Elsevier Ireland
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269442476605440
score 13.13397